Jun 24, 2026
14 MIN READ

NAD+ Zepbound Side Effects — What Happens When You Mix Them

Combining NAD+ supplements with tirzepatide requires careful consideration of drug interactions and individual tolerance. PlexusDx explains the science behind potential side effects and how genetic testing can guide safer treatment decisions.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 24, 2026
14 MIN READ

nad+ zepbound side effects — what happens when you mix them — PlexusDx GLP-1 education

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy production, and some people use it alongside tirzepatide to optimize metabolic health. However, mixing these compounds introduces interaction risks that deserve clinical attention, especially since tirzepatide already modulates multiple metabolic pathways through GLP-1 and GIP receptor activation.

How Tirzepatide and NAD+ Affect Your Metabolism Differently

Tirzepatide works by activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, which regulate appetite, blood sugar, and insulin secretion. NAD+, by contrast, functions as a cofactor in mitochondrial energy pathways and NAD+-dependent enzymes like sirtuins and PARPs. While these mechanisms operate in distinct cellular compartments, both influence insulin sensitivity and metabolic rate, creating potential for additive or competing effects.

When tirzepatide reduces caloric intake through appetite suppression, your body's energy demand decreases. Simultaneously, if NAD+ supplementation is intended to enhance cellular energy production or metabolic rate, this creates a biochemical tension: your brain is receiving signals to eat less while your mitochondria are being primed to work harder. This mismatch can stress metabolic regulation and contribute to fatigue, dizziness, or electrolyte imbalances in susceptible individuals.

Common Side Effects When Combining These Compounds

Tirzepatide alone produces gastrointestinal side effects in most users during dose escalation, including nausea, vomiting, constipation, and diarrhea. When NAD+ is added, these effects may worsen because NAD+ influences gut motility through sirtuin activation and mitochondrial function in intestinal cells. Some users report increased nausea or unpredictable bowel changes when both compounds are present, particularly if NAD+ dosing exceeds 500 mg daily.

Beyond GI symptoms, the combination can trigger metabolic stress signals: headaches, muscle aches, or general malaise during the first 2–4 weeks. This occurs because tirzepatide suppresses appetite while NAD+ may stimulate metabolic processes, forcing your body into a state of conflicting signals. Additionally, both compounds can influence blood pressure and heart rate through sympathetic nervous system activation, so individuals with pre-existing hypertension or cardiac conditions face higher risk of adverse events.

Genetic Factors That Predict Your Individual Risk Profile

Not everyone reacts to tirzepatide and NAD+ combination the same way because genetic variation in peptide and energy-metabolism pathways determines your tolerance threshold. PlexusDx Precision Peptide Genetic Test maps key variants in GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609)—polymorphisms that influence receptor sensitivity, appetite regulation, and metabolic rate. Individuals carrying loss-of-function GLP1R variants may experience exaggerated appetite suppression when tirzepatide is combined with NAD+ stimulation, while those with FTO variants predisposed to increased energy expenditure may tolerate the combination better.

Beyond peptide pathways, genetic variation in NAD+-consuming enzymes like SIRT1 and PARP1 affects how efficiently your cells use supplemental NAD+. The Precision Peptide Genetic Test evaluates 14 metabolic pathways and 49 peptides, providing clarity on whether your individual biology favors combination therapy or suggests a sequential, monitored approach instead. This precision-medicine insight reduces trial-and-error dosing and side effect burden.

Safe Practices When Using Tirzepatide With NAD+ Supplementation

If you choose to combine tirzepatide with NAD+, start tirzepatide at the lowest dose (0.25 mg weekly) and delay NAD+ introduction until your body has adapted to tirzepatide—typically 4 weeks into therapy. Keep NAD+ dosing conservative (250–500 mg daily) and avoid high-dose liposomal or IV formulations until tolerability is established. Monitor for new or worsening nausea, electrolyte symptoms (muscle cramps, fatigue), or changes in blood pressure, and report these to your prescriber immediately.

PlexusDx recommends obtaining the Precision Peptide Genetic Test after your first month of tirzepatide treatment. This $99 add-on test identifies your genetic predisposition to GLP-1/GIP sensitivity and metabolic flexibility, informing whether NAD+ augmentation is likely to enhance or complicate your treatment. If genetic markers suggest high GLP1R or GIPR sensitivity, your clinician may recommend delaying NAD+ or using microdose protocols to minimize interaction risk. Compounded tirzepatide from PlexusDx starts at $249/mo, ensuring consistent pharmaceutical quality while you optimize supplementation strategies with medical oversight.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I safely take NAD+ supplements while on tirzepatide?

NAD+ and tirzepatide can be combined under medical supervision, but they influence overlapping metabolic pathways, increasing risk of nausea, fatigue, and metabolic stress during dose adjustment. Starting tirzepatide first, waiting 4 weeks for adaptation, and then introducing low-dose NAD+ (250–500 mg daily) minimizes interaction risk. Genetic testing through PlexusDx helps predict your individual tolerance.

What side effects are most common with this combination?

Gastrointestinal symptoms (nausea, diarrhea) worsen when NAD+ is added because both compounds affect gut motility and intestinal mitochondrial function. Metabolic stress effects—headaches, fatigue, muscle aches—occur because tirzepatide suppresses appetite while NAD+ stimulates cellular energy production, creating conflicting signals. These typically resolve within 2–4 weeks if doses are managed conservatively.

How does the PlexusDx Precision Peptide Genetic Test help?

The test ($99 add-on after your first month) evaluates genetic variants in GLP1R, GIPR, FTO, and 46 other peptides across 14 metabolic pathways, predicting your receptor sensitivity and metabolic flexibility. This data informs whether NAD+ augmentation is likely to enhance weight loss or increase side effect burden, enabling your clinician to personalize dosing and sequencing.

Is compounded tirzepatide from PlexusDx safe for long-term NAD+ combination therapy?

Yes. PlexusDx tirzepatide is manufactured by licensed 503A compounding pharmacies, meeting pharmaceutical purity and potency standards. Consistent pharmaceutical quality ensures predictable drug interactions with NAD+, reducing unpredictable side effects. PlexusDx tirzepatide injection starts at $249/mo with HSA/FSA eligibility across all 50 states.

Should I stop NAD+ supplements when starting tirzepatide?

Not necessarily, but a staggered approach reduces side effect burden. Begin tirzepatide alone for 4 weeks, allowing your body to stabilize on appetite suppression and glucose control. Then introduce NAD+ at a low dose (250 mg daily) and increase slowly if well-tolerated. This sequential method clarifies which compound causes any side effects and allows safer combination management.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves